A Study of Ramucirumab (LY3009806) Plus MEDI4736 in Participants With Advanced Gastrointestinal or Thoracic Malignancies
Condition(s):Gastric Cancer; Gastroesophageal Junction Adenocarcinoma; Non-Small Cell Lung Cancer; Hepatocellular CarcinomaLast Updated:January 20, 2021Completed